The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has declared a quarterly dividend of $1.06 per common share, an increase ...

FRANKLIN LAKES, N.J., Feb. 5, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has unanimously ...

FRANKLIN LAKES, N.J., Oct. 20, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a global leader in medical technology, introduces the BD Incada™ Connected Care Platform, a new ...

FRANKLIN LAKES, N.J., Jan. 15, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced additional investments in its U.S.

The launch of the Liverty™ TIPS Stent Graft gives physicians flexibility to tailor treatment for patients. FRANKLIN LAKES, N.J., Oct. 28, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: ...

FRANKLIN LAKES, N.J., Jan. 27, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has ...

opens in a new window opens in a new window opens in a new window opens in a new window opens in a new window ...

Represents costs recorded to Other operating expense, net, incurred in connection with the separation of our former Biosciences and Diagnostic Solutions business and the combination of the business ...

Represents costs recorded to Other operating expense, net incurred in connection with the proposed combination of our Biosciences and Diagnostic Solutions business with Waters Corporation.

- Base Business Revenues denotes total revenues less estimated revenues for COVID-19 only diagnostic testing. - Base Business Organic Revenue Growth denotes Base Business Revenue less revenues ...

Amount reflects the estimated impact to adjusted diluted earnings per share for fiscal year 2025 from the proposed disposition of the Bioscience and Diagnostics Solutions business that will be ...

- Revenue Adjustment Impact reflects the recognition of accruals resulting from developments relating to the Italian government medical device pay back legislation, as well as another legal matter, ...